rhBSSL + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Replacement Therapy in Preterm Infants

Conditions

Replacement Therapy in Preterm Infants

Trial Timeline

Apr 1, 2008 → May 1, 2009

NCT ID

NCT00658905

About rhBSSL + Placebo

rhBSSL + Placebo is a phase 2 stage product being developed by Swedish Orphan Biovitrum for Replacement Therapy in Preterm Infants. The current trial status is completed. This product is registered under clinical trial identifier NCT00658905. Target conditions include Replacement Therapy in Preterm Infants.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00658905	Phase 2	Completed	Apr 1, 2008	May 1, 2009	Replacement Therapy in Preterm Infants
NCT00659243	Phase 2	Completed	Mar 1, 2008	Feb 1, 2010	Replacement Therapy in Preterm Infants

Competing Products

20 competing products in Replacement Therapy in Preterm Infants

See all competitors

Product	Company	Stage	Hype Score
DU-176b	Daiichi Sankyo	Phase 2	52
YM150 + Warfarin	Astellas Pharma	Phase 2	52
LY517717 + enoxaparin	Eli Lilly	Phase 2	52
Sugammadex	Merck	Approved	85
LNA043 + Placebo	Novartis	Phase 1	33
SBR759 + Sevelamer HCl + SBR759 + Sevelamer HCl	Novartis	Phase 2	52
conjugated estrogens/progestin (MPA)	Pfizer	Phase 1	32
rhBSSL + Placebo	Swedish Orphan Biovitrum	Phase 2	51
JNJ-70033093 25 mg + JNJ-70033093 50 mg + JNJ-70033093 100 mg + JNJ-70033093 200 mg + Placebo + Enoxaparin 40 mg	Bristol Myers Squibb	Phase 2	51
Enoxaparin sodium	Sanofi	Phase 3	76
HSK36273 + Heparin sodium	Haisco Pharmaceutical Group	Phase 2	49
Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA)	Bayer	Phase 3	74
Exacyl®	Bayer	Phase 3	74
Rivaroxaban (Xarelto, BAY59-7939)	Bayer	Pre-clinical	20
Gynodian® Depot (BAY86-5032) + BAY86-4980	Bayer	Phase 3	74
FLOSEAL Hemostatic Matrix + Standard of care	Baxter	Approved	82
Fibrin Sealant Vapor-Heated Solvent/Detergent-treated	Baxter	Phase 3	74
OMS302 + Placebo	Omeros Corporation	Phase 3	72
Part 1 OMS302 + Part 2 OMS302 + Part 2 Placebo	Omeros Corporation	Phase 3	72
OMS302 + Placebo	Omeros Corporation	Phase 3	72

Other Products from Swedish Orphan Biovitrum

Recombinant coagulation factor (rFVIIIFc)Approved

rFVIIIFcApproved

AnakinraApproved

Efanesoctocog alfaApproved

Kepivance (Palifermin)Approved